CADL vs DNA: stock comparison and AI forecast
Candel Therapeutics, Inc. (CADL) and Ginkgo Bioworks Holdings, Inc. (DNA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CADL Candel Therapeutics, Inc.
- Price
- $8.82 +15.0% · 6M
- Market Cap
- $675M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
DNA Ginkgo Bioworks Holdings, Inc.
- Price
- $10.76 +10.8% · 6M
- Market Cap
- $785M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- DNA is 1.2 times larger than CADL by market capitalization ($785M against $675M).
- Over the last six months CADL returned +15.0% and DNA +10.8%.
- DNA carries 1.36 times debt per unit of equity, against 0.65 times for CADL.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CADL | DNA |
|---|---|---|
| Market Cap | $675M | $785M |
| P/B Ratio | 5.35x | 1.87x |
| EPS | $-1.15 | $-5.64 |
| Book Value/Share | $1.65 | $6.24 |
| Revenue/Share | – | $1.66 |
| FCF/Share | $-0.75 | $-2.60 |
Profitability & Margins
| Metric | CADL | DNA |
|---|---|---|
| ROE | -70.2% | -69.2% |
| ROA | -42.5% | -29.4% |
| ROIC | -36.8% | -31.7% |
| Operating Margin | – | -259.9% |
| Net Margin | – | -260.0% |
| EBT Margin | – | -264.1% |
| Tax Rate | – | 0.2% |
Financial Health
| Metric | CADL | DNA |
|---|---|---|
| Current Ratio | 16.09x | 4.57x |
| D/E Ratio | 0.65x | 1.36x |
| Financial Leverage | 1.65x | 2.36x |
| Interest Coverage | -17.0x | -18.1x |
| Working Capital | $191M | $260M |
Cash Flow
| Metric | CADL | DNA |
|---|---|---|
| Operating Cash Flow | -$56M | -$170M |
| Free Cash Flow | -$57M | -$175M |
| Capital Spending | -$1M | -$5M |
| FCF/Sales | – | -156.3% |
| CapEx/Sales | – | 4.1% |
Operational Efficiency
| Metric | CADL | DNA |
|---|---|---|
| Asset Turnover | – | 0.11x |
| Receivables Turnover | – | 8.6x |
| Fixed Assets Turnover | – | 0.7x |
| Days Sales Outstanding | – | 42 days |
Income Statement
| Metric | CADL | DNA |
|---|---|---|
| Total Revenue | – | $112M |
| Operating Income | -$72M | -$291M |
| Net Income | -$89M | -$291M |
| R&D Expense | $49M | $216M |
Dividend & Shareholder Information
| Metric | CADL | DNA |
|---|---|---|
| Shares Outstanding | 77M | 67M |
CADL vs DNA: stock comparison and AI forecast
Which is bigger, CADL or DNA?
DNA is 1.2 times larger than CADL by market capitalization ($785M against $675M).
Which stock performed better over the last six months, CADL or DNA?
Over the last six months CADL returned +15.0% and DNA +10.8%.
Which one does Intratio's AI model rank higher, CADL or DNA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.